Objective: To compare bleeding complications in pregnant patients treated with low-molecular-weight heparin (LMWH) to untreated controls.
Introduction
Low-molecular-weight heparin (LMWH) for the prevention or treatment of thromboembolism has certain advantages over unfractionated heparin including greater bioavailability, more reliable pharmacokinetics, fewer bleeding complications and lower instances of osteoporosis and thrombocytopenia. [1] [2] [3] [4] [5] [6] [7] [8] [9] Owing to their predictable dose-response, LMWH does not require routine laboratory monitoring or dose adjustments in the majority of nonpregnant patients, thus allowing for more convenient regimens. 10 As they do not cross the placenta and are safe in breastfeeding, LMWH has gained widespread use in pregnancy. 11, 12 Systematic reviews suggest that enoxaparin therapy appears to be safe and efficacious when used in pregnant women. [13] [14] [15] [16] Because of the longer half-life, the use of LMWH in pregnancy introduces some peripartum management issues. One concern is a risk for significant neuraxial complications from regional anesthesia procedures. [17] [18] [19] Another issue is the potential for increased bleeding associated with delivery in anticoagulated patients, in particular postpartum hemorrhage (PPH), a common complication of childbirth and a leading cause of maternal morbidity and mortality. Although the exact definitions of PPH vary, postpartum anemia resulting in red blood cell (RBC) transfusion after vaginal delivery is less than 1% and after cesarean delivery ranges from 1 to 7%. 20 The objective of this study is to compare peripartum bleeding complications in pregnant women treated with LMWH to untreated pregnant controls matched for delivery route.
Study design
A case-control investigation of patients who received either prophylactic or therapeutic LMWH doses during pregnancy from 2001 to 2005 was performed. A keyword search of an electronic obstetric database identified the cases. Exclusion criteria were patient discontinuation of LMWH or pregnancy termination before the third trimester or delivery outside of the University of Illinois Medical Center at Chicago (UIMCC). Through the electronic database, controls were chosen in a 2:1 ratio to cases, matched for delivery route (cesarean vs vaginal), and selected as the next two consecutive deliveries without a history of thromboembolism or thrombophilia or current anticoagulation therapy. All patients were prescribed twice daily enoxaparin, except for one who took twice daily dalteparin for a prosthetic mitral valve (MVR). The primary outcome was the rate of PPH, defined as an estimated blood loss (EBL) >500 cm 3 for a vaginal delivery, an EBL >1000 cm 3 for a cesarean delivery, or a return to the operating room for postpartum bleeding complications within 14 days of delivery. Secondary outcomes included labor induction, regional anesthesia choices, gestational age at delivery, delivery routes, change in hemoglobin (predelivery and within 24 h after delivery), RBC transfusions, thrombotic events, congenital anomalies and neonatal mortality.
Statistical analyses, performed with SAS statistical software (Version 8.2; Cary, NC), included the Student's t, w 2 and Fishers exact tests; P<0.05 was statistically significant. Weighted odds ratios (ORs) were calculated (with respect to matching criteria) with 95% confidence intervals (CIs) by the Mantel-Haenszel test for anesthesia type, PPH and RBC transfusion. Linear and logistic regression analyses were performed to control for potential confounders. This study was approved by the UIMCC Institutional Review Board.
Results
Of the 69 pregnancies identified, 14 were excluded (six elective terminations <22 weeks, two spontaneous abortions <20 weeks, three transfers of care to another hospital and three discontinuations of LMWH before the third trimester). Forty-nine women treated with LMWH during pregnancy delivered 55 infants during the 4-year study period. The most common indication for treatment, as shown in Table 1 , was a history of a deep vein thrombosis (DVT) or pulmonary embolism (PE) or both either in a previous pregnancy or a nonpregnant state (26/55, 47.3%) . For the 38 patients tested for either an inherited or acquired thrombophilia, the results were positive in 13 (34.2%). The types of thrombophilia included protein S deficiency where the diagnosis was confirmed in the nonpregnant state (n ¼ 4 in 6 pregnancies), heterozygous Factor V Leiden (FVL) mutation (n ¼ 4), antiphospholipid antibody syndrome (n ¼ 3), heterozygous methylenetetrahydrofolate reductase (MTHFR) mutation (n ¼ 1), and antithrombin deficiency (n ¼ 1). The patient with the MTHFR mutation also had a PE during the pregnancy. The dosing regimen was therapeutic in 37/55 (67.3%) cases, defined as an anti-Xa level maintained between 0.6 and 1.0 IU/ml and between 1.0 and 1.5 IU/ml for three patients with a MVR. The remaining patients were treated with a prophylactic LMWH regimen, defined as a peak anti-Xa level maintained between 0.3 and 0.6 IU/ml.
There was a greater number of obese gravidas (prepregnancy body mass index >30 kg/m 2 ) in the cases compared to the controls; OR 3.91, CI 1.70 to 9.09 ( Table 2 ). The decision to switch patients to twice daily subcutaneous unfractionated heparin injections (15/55, 27%) at 36±1.3 weeks or continue on LMWH until delivery (40/55, 73%) was at the discretion of the managing physician. The average time from the last dose of anticoagulation until delivery was the same in these two groups (34±15 h, median 34 h; P ¼ 0.98). Greater than 24 h lapsed from the time of the last dose of anticoagulation until delivery in 70% of the cases.
No fetal demises or complications from regional anesthesia occurred among either study group. Only one patient was not eligible for an epidural because of a recent LMWH injection. The cases were more likely to have a labor induction, 25/55 (45%) vs 29/110 (26%), P ¼ 0.01. The overall cesarean delivery rate was 20/55 (37%). Although gestational age at delivery was significantly lower in the cases compared to controls, the majority of cases delivered after 37 weeks. As shown in Table 3 , there was no statistical difference in EBL (296±146 vs 307±112 cm 3 , P ¼ 0.62 for vaginal delivery; 688±252 vs 765±313 cm 3 , P ¼ 0.34 for cesarean delivery), PPH (6/55, 11% vs 9/110, 8.2%; OR 1.37, 95% CI 0.16 to 11.5) or postpartum RBC transfusion (3/55, 5.4% vs 4/110, 3.6%; OR 1.50, 95% CI 0.3 to 7.48) between the cases and controls, respectively. In a linear regression model, the cases lost an average of 51 cm 3 less blood than controls (P ¼ 0.15) after controlling for race, primigravidity, gestational age, induction of labor and delivery type. The cases were no more likely to have a PPH (P ¼ 0.89) nor require a RBC transfusion (P ¼ 0.94) after controlling for the same variables in a logistic regression model. Postpartum anticoagulation, consisting of LMWH and/or warfarin was restarted at an average of 18±11 h (median 16 h) after delivery.
The bleeding complications among the cases were attributed to a retained placental cotyledon diagnosed on postpartum day 7, two instances of lacerations after operative vaginal deliveries (EBL 700 cm 3 at delivery in both), and adhesions complicating a repeat cesarean delivery which required general anesthesia for a recent LMWH dose (patients 1 to 4 in Table 4 ). The fifth patient returned postpartum day 12 with vaginal bleeding, but a dilation and curettage (D&C) did not show retained products of conception; her anti-Xa level was 0.79 IU/ml greater than 12 h after a 90 mg enoxaparin dose. She presented 5 days later, now with a hemoglobin of 5 g/dl, a peak anti-Xa level of 1.36 IU/ml and was transfused three units of RBC. The last patient, whose prophylactic LMWH dose was greater than 48 h before surgery, returned to the operating room 8 h after a classical cesarean delivery for repair of the uterine incision and a retroperitoneal hematoma. This patient, with antithrombin deficiency, was poorly compliant with her anticoagulation regimen and also complained of chest pain postoperative day 10. The treatment for her PE, confirmed by chest CT, included 6 months of warfarin for an INR goal of 2.0 to 3.0. The other thrombotic event occurred in a patient with a PE history in a previous pregnancy, morbid obesity, hypertension and pregestational diabetes. She had a vaginal birth after cesarean at 36 weeks followed by initiation of warfarin with 80 mg enoxaparin twice daily 11 h after delivery. The last dose of LMWH was 33 h before delivery and the anti-Xa level most proximate to delivery was 0.61 IU/ml. The patient died postpartum day 4 from acute respiratory failure secondary to a PE. The birth weights (3086±813 vs 3142±733 g, P ¼ 0.65) and length of neonatal hospital stay >4 days (16.4 vs 1.8%; OR 1.55, 95% CI 0.55 to 4.12) were similar between the cases and controls. There were no differences in congenital anomalies; the one major anomaly in the treated group was a hypoplastic left heart. The rate of neonatal mortality was also similar 2/55, 3.6% vs 1/110, 0.9%; P ¼ 0.26 between the cases and controls, respectively.
Discussion
In this case-control study, the use of LMWH during pregnancy for either prophylaxis or treatment of thromboemboli was not associated with increased delivery EBL, PPH or blood transfusions compared with controls matched for delivery route. Patients treated with LMWH were more likely to be obese than the controls, a factor that may contribute to higher cesarean deliveries (37%) and, in turn, blood loss. In general, the cases had more medical complications and obesity may have represented one of many factors contributing to an increased risk for thrombotic events in these patients. The cases were more likely to have a labor induction, which could also account for the increased cesarean deliveries. Of the cases undergoing labor induction at term, half were indicated for optimal management of their anticoagulation including the option of having an epidural during labor, but they also shared other high risk factors such as diabetes or fetal growth restriction that contributed to an earlier delivery.
Previous studies have addressed the safety profile of LMWH in pregnancy. Nelson-Piercy et al. 21 reported a 5.8% (4/69) prevalence of PPH (defined as an EBL >500 cm 3 for vaginal delivery) and two of these patients required blood transfusions for obstetric reasons, not for abnormal coagulation studies. A systematic review of 728 pregnant women treated with LMWH reported 27 (3.7%) bleeding complications. 15 In a smaller review of 57 women prophylaxed or treated with enoxaparin, four (7%) had PPH; vaginal lacerations were the etiologies in two cases. 22 In a large retrospective analysis of 624 pregnancies in 604 women treated with enoxaparin, there were 32 hemorrhages (5.1%) at delivery. 23 None were considered serious and only two (1.3%) were possibly related to enoxaparin. In the study of Rowan et al. 24 4/52 (7.7%) women had a PPH (EBL >500 cm 3 for vaginal or EBL >1000 cm 3 for cesarean delivery), but none required transfusion, and all stopped enoxaparin at least 44 h before delivery. Maslovitz et al. 25 described a cohort of 284 gravidas treated with LMWH and 16 132 untreated pregnant women. Postpartum hemorrhage, defined by a decrease of X10% in hematocrit 24-72 h after delivery, was rare, 2.1% (n ¼ 6) in treated and 1.9% (n ¼ 306) in controls. 25 In four cases of PPH, the last LMWH dose was more than 24 h before delivery.
The peripartum bleeding complications in the current study were not significantly different between the cases and controls and routine obstetric factors such as a retained placenta and extensive perineal lacerations accounted for the majority of complications. However, the PPH rate (11%) among the cases was higher than all previous investigations. 10,15,21 -25 Our definition of PPH, including bleeding occurrences beyond the immediate delivery period, likely accounted for this difference. We believe it was important to include this time period regarding the safety of LMWH in pregnancy as the postpartum presents the greatest risk period for thromboembolic events and continued anticoagulation is indicated.
There is no standard of care for anticoagulation management in the peripartum, but switching to unfractionated heparin at 36 weeks or continuing with LMWH until an induction of labor or planned cesarean are both acceptable practices. The negative aspects of the former approach include increased side effects along with frequent activated partial thromboplastin time monitoring and dosing adjustments. The advantage of unfractionated heparin in this setting is that protamine can reverse its effects. A scheduled labor induction, providing the physician with more control, may optimize anticoagulation surrounding the time of delivery and decrease the occurrence of thromboembolism and bleeding complications. However, if increased labor inductions lead to increased cesarean deliveries, then the potential for improved morbidity is lessened with the increased risks of major hemorrhage or thromboembolism associated with cesarean delivery. Our numbers were too small to separately analyze outcomes with respect to LMWH management at term.
Nearly 90% of our patients restarted LMWH after delivery, usually at the same dose they took just before delivery. The patient who presented postpartum day 12 with vaginal bleeding and again 5 days later with supratherapeutic anti-Xa levels, may have benefited from earlier postpartum follow-up and anti-Xa levels. On the basis of anti-Xa levels, no dose adjustments were necessary from the initial 90 mg enoxaparin twice daily dose prescribed throughout the antepartum course. The two patients with PE did not have anti-Xa levels postpartum; verification may have determined therapy adherence and adequacy of treatment. One of these patients was not anticoagulated for more than 4 days due to a prolonged labor and a postoperative retroperitoneal hematoma. For patients at high risk for thrombotic events and expected prolonged labors, one should consider both anticoagulation and other nonpharmacologic prophylaxis measures such as sequential compression devices and compression stockings during labor.
Two of our patients had a secondary PPH (hemorrhage occurring more than 24 h after delivery). Postpartum anticoagulation dosing varies widely and there are no definitive studies to guide one's approach in such situations. 26 With respect to LMWH, it is generally considered safe to resume therapy within 12 h of an uncomplicated delivery, but no studies have addressed dosing parameters or anti-Xa level monitoring in the postpartum patient. 17 Given the dramatic changes in weight and drug volume distribution immediately postpartum, it would not be surprising if dosing requirements decreased significantly. One option that could minimize thrombotic events and bleeding complications is to recalculate the weight-based dose and check the anti-Xa level within the first 2 to 3 days postpartum.
Bleeding complications of patients receiving prophylactic and therapeutic doses of LMWH were compared together because the number of patients in each group was small. This was justified in that a recent study reported that postpartum bleeding was similar between patients taking 40 mg (n ¼ 89) or 80 mg (n ¼ 91) of enoxaparin daily (1% in each group). 27 Although an 'EBL' number accompanied every delivery record, EBL is not an objective reflection of blood loss unless it is quantitatively measured. As such, this study had the same limitations of many investigations regarding bleeding complications and pregnancy. In addition, many patients in the control group who delivered vaginally did not have postpartum blood counts; therefore, a comparison was not performed between these two subgroups with respect to hemoglobin levels.
A clinician may manage the third stage of labor differently in an anticoagulated patient either by administering prophylactic agents (i.e., misoprostol) or intervening earlier to prevent PPH. This was another potential bias not controlled for in the study design. Cases were matched to controls according to only delivery route in both the study design and analysis. Although variables such as LMWH dosing (therapeutic vs prophylactic), labor induction, and management of anticoagulation in the peripartum are also important for outcome analysis, matching for them was thought to add excessive bias. Even after controlling for confounding variables in a regression analysis, there were no significant differences between the two groups with respect to EBL, PPH and transfusions. A 2:1 ratio of controls to cases was chosen for improved statistical power; although the power to detect differences in PPH and RBC transfusion was still small, 10%. We performed a post hoc power analysis using our observed PPH rate in the control group of 8.2%. To detect a 50% difference would require a sample size of 153 with a power of 80%. Clearly, a larger sample size would be desirable, but with our rate of collection, this would require another 10 years of patients. Thus, a multicenter prospective cohort or nested case-control study would likely be the best way to address this question.
The similar distribution of bleeding complications between the cases and controls support the claim that bleeding was unrelated to the coagulation status of the patient, but rather was a result of well-recognized complications of vaginal and operative deliveries. However, hemorrhagic complications associated with LMWH administration during pregnancy were not uncommon. Several questions remain regarding the optimal time to discontinue anticoagulation before delivery. Further studies should address appropriate dosing parameters for LMWH, especially in the postpartum, to balance the risks of postpartum thromboembolism and bleeding complications.
